We are pleased to be recommended again in the latest…
Elisabeth Greiner
Partner
Dr. rer. nat. Mag. pharm.
Dr. Elisabeth Greiner is a German and European Patent Attorney and partner at df-mp. A primary focus of her practice is on opposition and litigation of German and European patents, in particular, in the fields of pharmaceuticals, chemistry and biotechnology, and provides corresponding infringement and validity opinions. She has successfully enforced and/or defended her clients’ interests in various high profile patent disputes.
+ 49 89 210 296 0
elisabeth.greiner@df-mp.com
Elisabeth Greiner
Partner
Dr. rer. nat. Mag. pharm.
Dr. Elisabeth Greiner is a German and European Patent Attorney and partner at df-mp. A primary focus of her practice is on opposition and litigation of German and European patents, in particular, in the fields of pharmaceuticals, chemistry and biotechnology, and provides corresponding infringement and validity opinions. She has successfully enforced and/or defended her clients’ interests in various high profile patent disputes.
+ 49 89 210 296 0
elisabeth.greiner@df-mp.com
practice areas.
Dr. Greiner's practice focuses on prosecution, opposition and litigation matters concerning German and European patents. With her experience in contentious proceedings, Elisabeth assists her clients with drafting, prosecuting, and assessing patent applications in various fields of life-sciences and chemistry, and has furthermore comprehensive expertise in advising on supplementary protection certificates and coordinating the filing and prosecution of corresponding applications in Germany and throughout Europe.
Elisabeth holds a PhD in pharmaceutical sciences from the University of Innsbruck, Austria, where she also received her doctorate degree for her work in the field of synthetic medicinal chemistry on CNS drugs. Elisabeth honed her in skills as medicinal chemist during her postdoctoral study at the national Institute of Health in Bethesda, MD, USA.
We are delighted to be listed again in this year’s…
df-mp joins the ranks of “highly recommended” patent law firms…
We proudly announce that df-mp is among the most recommended patent…
Sucess for Ceva: The company is now allowed to market its…
df-mp is proud to receive another five IP stars this…
The pharmaceutical companies Hexal and Teva may continue to sell…
The patent disputes of our client Hexal AG over the…
df-mp is delighted that five partners have been awarded the…
df-mp is recommended in the current JUVE-Handbook with the highest…
admissions.
- German Patent Attorney
- European Patent Attorney
- European Trademark Attorney
- European Design Attorney
- Unified Patent Court (UPC) representative
EDUCATION
- Pharmacy, University of Innsbruck (Mag. pharm.)
- Doctorate degree in medicinal chemistry, University of Innsbruck, (Dr. rer. nat.)
- Postdoctoral research fellow at the Laboratory of Medicinal Chemistry at the National Institute of Health (NIH) in Bethesda, MD, U.S.A.
AWARDS AND RECOMMENDATIONS.
- Author and co-author of numerous scientific publications in the field of organic and medicinal chemistry
- Organizer of IP-workshops
- Lecturer of IP-seminars at the MCI (Management Center Innsbruck, the entrepreneurial school, Austria)
- Elisabeth has been listed in the IAM patent 1000 as recommended individual („one of the top pharmaceutical patent practitioners“, „outstanding at communicating her technical points to technical judges; her pleading style is genuinely impressive. She is hard-working, dedicated, articulate and creative“), JUVE-Handbook („cooperative, friendly and highly experienced in infringement cases”, “impressive in pharmaceuticals cases”), and also regularly as IP star in the Managing Intellectual Property Magazine.
curriculum vitae.
Since 2012
Partner at df-mp
Since 2008
Patent attorney at df-mp
2005-2008
Legal trainee at df-mp, the German Patent and Trademark Office (DPMA) and the German Federal Patent Court (BPatG)
2001-2005
Postdoctoral research fellow in the Laboratory of Medicinal Chemistry at the National Institute of Health (NIH) in Bethesda, MD, U.S.A.
1999-2000
Doctorate Degree (with honors) in Medicinal Chemistry from University of Innsbruck, Institute of Pharmacy, Austria
1996
Degree (Mag.pharm. with honors) in Medicinal Chemistry from University of Innsbruck, Institute of Pharmacy, Austria
Representative cases.
- Glatirameracetat / Copaxone®: infringement proceedings, utility model cancellation proceedings
- Fulvestrant / Faslodex®: Formulation patents, nullity proceedings (BGH X ZR 59/17), opposition proceedings, various infringement proceedings
- Fulvestrant / Faslodex®: Patent of use, infringement proceedings
- Calcipotriol – Betamethason / Calcipotriol comp Hexal®: several opposition proceedings, infringement proceedings
- DMF / Tecfidera®: various opposition procedures
- Anti-VEGF Antibody / Avastin® Xeloda®: opposition procedures
association memberships.
publications.
- Greiner, E.; Schottenberger, H.; Wurst, K.; Schmidhammer, H.: Novel Class of Morphinans with Acrylonitrile Incorporated Substructures as Key Intermediates for non-Oxygen-Bridged Opioid Ligands. J. Am. Chem. Soc. 2001, 123, 3840-3841.
- Greiner, E.; Atkinson, A.J.J.; Ayala, A.; Chrousos, G.P.; Contoreggi, C.; Eckelman, W.C.; Gold, P.W.; Habib, K.E.; Jacobson, A.E.; Webster, E.L.; Rice K.C.: Synthesis of Doubly 13C-Labelled Antalarmin Isotopomers for Pharmacokinetic Studies. J. Labelled Cpd. Radiopharm. 2002, 45, 637-645.
- Greiner, E.; Prisinzano, T.; Johnson II, E.M.; Dersch, C.M.; Marcus, J.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. J. Med. Chem. 2003, 46, 1465-1469.
- Greiner, E.; Spetea, M.; Krassnig, R.; Schuellner, F.; Aceto, M.; Harris, L.S.; Traynor, J.R.; Woods, J.H.; Winger, G.; Coop, A.; Schmidhammer, H.: Synthesis and Biological Evaluation of 14-Alkoxymorphinans - Part 18 - N-Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties: Extending the Scope of Common Structure-Activity Relationships. J. Med. Chem. 2003, 46, 1758-1763.
- Jagoda, E.; Contoreggi, C.; Lee, M.; Kao, C.K.; Szajak, L.P.; Listwak, S.; Gold, P.W.; Chrousos, G.P.; Greiner, E.; Kim B.M., Jacobson, A.E.; Rice K.C.: Eckelman, W.: Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: Synthesis of [Br-76]MJL-1-109-2. J. Med. Chem. 2003, 46, 3559-3562.
- Greiner, E.; Folk, J.E.; Jacobson, A.E.; Rice, K.C.: A novel and facile preparation of bremazocine enantiomers through optically pure N-norbremazocines. Bioorg. Med. Chem. 2004, 12, 223-238.
- Seggewiss, R.; Lore, K.; Greiner E.; Magnusson M.K.; Price D.A.; Douek D.C.; Dunbar C.E.; Wiestner A.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 15, 2473-2479.
- Greiner, E.; Boos, T.L.; Prisinzano T.E.; De Martino, M.G.; Zeglis, B.; Dersch, C.M.; Marcus, J.; Partilla, J.S.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Design and Synthesis of Promiscuous High Affinity Monoamine Transporter Ligands: An Attempt at Unraveling Transporter Selectivity. J. Med. Chem. 2006 Mar 9;49(5):1766-72.
- Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008 Apr 15;14(8):2484-91.
YOUR PARTNER
For Patents. Trademarks. Designs.
df-mp Patentanwälte Rechtsanwälte PartG mbB © 2025 df-mp | Your partner for Patents. Trademarks. Designs. All Rights Reserved.
